Expression of sphingosine kinase 1 in breast cancer and its clinical significance

doi:10.3877/cma. j. issn.1674-0807.2015.02.005

Abstract

Abstract:

Objective

To investigate the expression of sphingosine kinase 1 (Sphk1) and its correlation with clinicopathological characteristics and with E-cadherin expression in breast cancer.

Methods

We collected 171 cases of breast tissue specimens resected in Department of Breast Surgery, Chongqing Cancer Institute from September 2003 to May 2006, including 20 cases of breast fibroadenoma and 151 cases of invasive ductal carcinoma. Immunohistochemistry was used to detect Sphk1 and E-cadherin expression in all breast tissue specimens. The correlations of Sphk1 expression with clinicopathological characteristics and E-cadherin expression were analyzed. The count data were processed using χ² test, rank data using rank sum test.

Results

Sphk1 was positive in 114 cases of breast cancer (75.50%,114/151), negative in all 20 cases of breast fibroadenoma; the difference was significant (χ² =45.298,P=0.000); Sphk1 expression was significantly associated with lymph node metastasis(Z=-6.122,P=0.000), ER (χ² =4.478,P=0.034)and HER-2 expression(χ² =7.313,P=0.013), not correlated with the patient’ age(χ² =2.791,P=0.095), menopausal status(χ² =0.010, P=0.919), tumor diameter (Z=-0.249, P=0.804)or PR expression(χ²=0.740,P=0.390). In all patients with invasive ductal carcinoma, the patients with different E-cadherin and Sphk1 expression status showed a significantdifference in lymph node metastasis (χ²= 17.187, P=0.001). The positive rate of lymph node metastasis was 85.71%(18/21) in the patients with E-cadherin (-) and Sphk1 (+) ,30.77% (8/26) in the patients with Ecadherin (+) and Sphk1 (-), indicating a significant difference (χ² = 14.189, P＜0.008).

Conclusion

Sphk1 may play an important role in the development and metastasis of breast cancer, which can be a useful indicator to predict the biological behaviors of breast cancer.

Key words: Breast neoplasms, Neoplasm invasiveness, E-cadherin, Sphingosine kinase 1

Xiaodong Zheng, Yan Zhang, Huiying Fang, Minghao Wang, Yi Zhang, Jun Jiang. Expression of sphingosine kinase 1 in breast cancer and its clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2015, 09(02): 96-100.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2015.02.005

https://zhrxbzz.cma-cmc.com.cn/EN/Y2015/V09/I02/96

Figures/Tables 4

References 20

[1]	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin,2013,63(1):11-30.
[2]	Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate[J]. Science, 2007, 316(5822):295-298.
[3]	Okada T, Kajimoto T, Jahangeer S, et al. Sphingosine kinase/sphingosine 1-phosphate signaling in central nervous system[J]. Cell Signal,2009,21(1):7-13.
[4]	张毅, 周艳, 王姝姝, 等. Sphk1 在乳腺不典型增生及乳腺癌中的表达及意义[J/CD]. 中华乳腺病杂志:电子版,2010,4(2):49-51.
[5]	Lakhani SR,Ellis IO,Schnitt SJ,et al. WHO classification of tumours of the breast[M]. Lyon: IARC Press,2012.
[6]	Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual[M].7th ed. New York:Springer,2010:347-376.
[7]	Hammond ME,Hayes DF,Dowsett M,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol,2010,28(16):2784-2795.
[8]	Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol,2013,31(31):3997-4013.
[9]	Ochiumi T, Tanaka S, Oka S, et al. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma [ J]. Int J Oncol, 2004,24 (3):539-547.
[10]	Kohama T, Olivera A, Edsall L, et al. Molecular cloning and functional characterization of murine sphingosine kinase[J]. J Biol Chem,1998,273(37):23722-23728.
[11]	Nava VE, Lacana E, Poulton S, et al. Functional characterization of human sphingosine kinase-1 [J]. FEBS Lett,2000,473(1):81-84.
[12]	Liu H, Sugiura M, Nava VE, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform[J]. J Biol Chem, 2000, 275(26):19 513-19 520.
[13]	Johnson KR, Johnson KY, Crellin HG, et al.Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue [J]. J Histochem Cytochem,2005,53(9):1159-1166.
[14]	Pyne NJ, Pyne S. Sphingosine 1 phosphate and cancer[J].Nat Rev Cancer,2010,10(7):489-503.
[15]	Guan H, Song L, Cai J, et al. Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells[J]. PLoS One,2011,6(5):e19946.
[16]	Nava VE, Hobson JP, Murthy S, et al. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells[J]. Exp Cell Res,2002,281(1):115-127.
[17]	Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, betacatenin and ZEB1 in malignant progression of cancer [J].Cancer Metastasis Rev,2009,28(1-2):151-166.
[18]	Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas[J]. Clin Exp Metastasis,2008,25(6):621-628.
[19]	Bao M, Chen Z, Xu Y, et al. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma [J]. Liver Int,2012,32(2):331-338.
[20]	Ruckhäberle E, Rody A, Engels K, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer [J].Breast Cancer Res Treat,2008,112(1):41-52.

组别	例数	淋巴结状态(例)		χ²值	P值
组别	例数	+	-	χ²值	P值
E-cadherin(+)Sphk1(+)	93	55	38	17.187	0.001
E-cadherin(-)Sphk1(+)	21	18	3
E-cadherin(+)Sphk1(-)^a	26	8	18
E-cadherin(-)Sphk1(-)^b	11	9	2

组别	例数	淋巴结状态(例)		χ²值	P值
组别	例数	+	-	χ²值	P值
E-cadherin(+)Sphk1(+)	93	55	38	17.187	0.001
E-cadherin(-)Sphk1(+)	21	18	3
E-cadherin(+)Sphk1(-)^a	26	8	18
E-cadherin(-)Sphk1(-)^b	11	9	2

Please choose a citation manager

Content to export